Showing 1 - 4 results of 4 for search 'Michael T. Hotchkin', query time: 0.02s Refine Results
  1. 1
    Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

    Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catal... by Matthew C Kiernan, William Huynh, Steve Vucic, Parvathi Menon, Austin Rynders, Karen S Ho, Robert Glanzman, Michael T Hotchkin

    Published 2021-01-01
    Get full text
    Article
  2. 2
    Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extensionResearch in context

    Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extensionResearch i... by Steve Vucic, Parvathi Menon, William Huynh, Colin Mahoney, Karen S. Ho, Alan Hartford, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Robert Glanzman, Michael T. Hotchkin, Matthew C. Kiernan

    Published 2023-06-01
    Get full text
    Article
  3. 3
    Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials

    Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials by Jimin Ren, Richard B. Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Karen S. Ho, Peter V. Sguigna, Robert Glanzman, Michael T. Hotchkin, Richard B. Dewey, Benjamin M. Greenberg

    Published 2023-12-01
    Get full text
    Article
  4. 4
    Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials

    Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials by Jimin Ren, Richard B. Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Karen S. Ho, Peter V. Sguigna, Robert Glanzman, Michael T. Hotchkin, Richard B. Dewey, Benjamin M. Greenberg

    Published 2024-01-01
    Get full text
    Article

Search Tools: